Investors reacted positively overall to Gilead Sciences' (NASDAQ: GILD) announcement earlier this year that Dan O'Day would be the big biotech's next CEO. O'Day claims a solid track record at Roche, most previously serving as CEO of Roche Pharmaceuticals.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,